GIACOMELLI, ROBERTO
 Distribuzione geografica
Continente #
AS - Asia 15.334
NA - Nord America 8.137
EU - Europa 3.915
SA - Sud America 1.806
AF - Africa 222
OC - Oceania 55
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 29.472
Nazione #
SG - Singapore 8.457
US - Stati Uniti d'America 7.744
CN - Cina 2.685
HK - Hong Kong 2.216
IT - Italia 1.806
BR - Brasile 1.353
VN - Vietnam 766
GB - Regno Unito 646
FR - Francia 538
BD - Bangladesh 395
DE - Germania 261
IN - India 221
CA - Canada 211
AR - Argentina 182
NL - Olanda 116
ID - Indonesia 113
MX - Messico 98
EC - Ecuador 83
ZA - Sudafrica 80
TR - Turchia 77
UA - Ucraina 74
JP - Giappone 73
CO - Colombia 59
ES - Italia 57
IQ - Iraq 56
RU - Federazione Russa 53
AU - Australia 50
PL - Polonia 45
CL - Cile 39
FI - Finlandia 37
PY - Paraguay 36
SA - Arabia Saudita 34
CZ - Repubblica Ceca 32
MA - Marocco 32
AT - Austria 31
SE - Svezia 29
PE - Perù 26
PK - Pakistan 25
EG - Egitto 23
JM - Giamaica 23
MD - Moldavia 22
PT - Portogallo 22
TN - Tunisia 22
UZ - Uzbekistan 20
RO - Romania 19
PH - Filippine 18
VE - Venezuela 16
IL - Israele 14
JO - Giordania 14
NP - Nepal 14
KE - Kenya 13
KZ - Kazakistan 13
LT - Lituania 13
OM - Oman 12
CR - Costa Rica 11
DK - Danimarca 11
IR - Iran 11
AE - Emirati Arabi Uniti 10
BG - Bulgaria 10
LB - Libano 10
AL - Albania 9
DZ - Algeria 9
GT - Guatemala 9
HN - Honduras 9
IE - Irlanda 9
AZ - Azerbaigian 8
CH - Svizzera 8
DO - Repubblica Dominicana 8
ET - Etiopia 8
TH - Thailandia 8
BE - Belgio 7
GR - Grecia 7
MY - Malesia 7
SK - Slovacchia (Repubblica Slovacca) 7
SV - El Salvador 7
UY - Uruguay 7
EE - Estonia 6
KR - Corea 6
KW - Kuwait 6
RS - Serbia 6
BA - Bosnia-Erzegovina 5
GH - Ghana 5
LU - Lussemburgo 5
LV - Lettonia 5
SN - Senegal 5
BO - Bolivia 4
CG - Congo 4
PA - Panama 4
SI - Slovenia 4
TW - Taiwan 4
AF - Afghanistan, Repubblica islamica di 3
BH - Bahrain 3
CY - Cipro 3
HU - Ungheria 3
IS - Islanda 3
LK - Sri Lanka 3
NI - Nicaragua 3
PS - Palestinian Territory 3
QA - Qatar 3
SY - Repubblica araba siriana 3
Totale 29.403
Città #
San Jose 2.937
Hong Kong 2.192
Ashburn 1.833
Singapore 1.710
Rome 1.283
Hefei 1.104
Boardman 617
London 527
Lauterbourg 473
Beijing 471
Shanghai 357
Dallas 346
Ho Chi Minh City 294
Council Bluffs 207
New York 157
Hanoi 149
Los Angeles 133
São Paulo 113
Santa Clara 106
Pune 97
San Francisco 94
Amsterdam 78
Toronto 71
Munich 61
Washington 53
Tokyo 52
Seattle 51
Mexico City 44
Milan 42
Naples 42
Haiphong 37
Warsaw 37
Frankfurt am Main 36
Montreal 36
Brooklyn 35
Da Nang 34
Rio de Janeiro 34
Brasília 32
Las Vegas 31
Baghdad 30
Ankara 29
Johannesburg 28
Buffalo 27
Chicago 27
Guayaquil 27
Quito 24
Stockholm 24
Turku 23
Bari 22
Biên Hòa 22
Guangzhou 22
Nuremberg 21
Porto Alegre 21
Atlanta 20
Curitiba 20
Thái Bình 20
West Jordan 20
Brno 19
Chennai 19
Phoenix 19
Boston 18
Buenos Aires 18
Cape Town 18
Hải Dương 18
Jinan 18
Belo Horizonte 17
Campinas 17
Manchester 17
Sydney 17
Vienna 17
Guarulhos 16
Lima 16
Tashkent 16
Charlotte 15
Hangzhou 15
Jakarta 15
Changsha 14
Kingston 14
Riyadh 14
Can Tho 13
Dhaka 13
Helsinki 13
Manaus 13
Medellín 13
Melbourne 13
Turin 13
Amman 12
Hortolândia 12
Lấp Vò 12
Paris 12
Salvador 12
Tunis 12
Bengaluru 11
Bogotá 11
Bologna 11
Cairo 11
Florence 11
Fortaleza 11
Madrid 11
Nairobi 11
Totale 17.051
Nome #
Fibroblast expression of CD248 may contribute to exacerbate microvascular damage during systemic sclerosis 267
------- 242
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 235
Covid-19 And Rheumatic Autoimmune Systemic Diseases: Role of Pre-Existing Lung Involvement and Ongoing Treatments 233
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 220
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 220
A comprehensive review on adult onset Still's disease 214
AB0550 PHENOTYPE OF BIOPSY-PROVEN PATIENTS WITH PRIMARY SJÖGREN SYNDROME LACKING RO AUTOANTIBODIES: HIGH FREQUENCY OF DRYNESS SYMPTOMS WITH LOW SYSTEMIC ACTIVITY (BIG DATA SJÖGREN PROJECT) 207
Cardiometabolic multimorbidity may identify a more severe subset of rheumatoid arthritis, results from a “real-life” study 204
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis 204
Adipose stromal vascular fraction and regenerative therapy in SSc: Response to the article by Magalon et al 200
Cytokine profile, ferritin, and multi-visceral involvement characterise macrophage activation syndrome during adult-onset Still's disease 195
Aberrant expression of IL-22RA1 on hematopoietic cells as immunologically signature of primary sjogren’s syndrome and sjogren-associated non-hodgkin lymphomas 193
Clinical characteristics of obese patients with adult-onset Still's disease. Data from a large multicentre cohort 192
AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN’S SYNDROME (PSS) 191
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 191
Impaired immunogenicity to COVID-19 vaccines in autoimmune systemic diseases. High prevalence of non-response in different patients' subgroups 182
Prevalence and Death Rate of COVID-19 in Autoimmune Systemic Diseases in the First Three Pandemic Waves. Relationship with Disease Subgroups and Ongoing Therapies 177
Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry 175
A3.1 Pathogenic role of IL-17 producing double negative (DN) T cells in primary sjögren’s syndrome 174
Clinical correlates of a subset of anti-fibroblast antibodies in systemic sclerosis 167
2-Arachidonoylglycerol Reduces the Production of Interferon-Gamma in T Lymphocytes from Patients with Systemic Lupus Erythematosus 165
Adult-onset Still's disease with elderly onset: results from a multicentre study 164
Bosentan effect on echocardiographic systolic pulmonary arterial pressure in systemic sclerosis-related pulmonary hypertension: a systematic review and metanalysis 164
2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 153
Clinical and subclinical atherosclerosis in patients with systemic sclerosis: an observational, multicentre study of GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) 135
ASSESSING PRO-INFLAMMATORY PROPERTIES OF H-FERRITIN BY EX VIVO AND IN VITRO OBSERVATIONS 124
Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study 122
The clinical assessment of lung involvement in patients with Still’s disease, results from the multicentre international AIDA Network Still’s Disease Registry 120
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 118
Association Between Minor Salivary Gland Biopsy During Sjӧgren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis 118
The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmod 118
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 116
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 116
Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study 114
Cardiovascular Risk Prediction in Ankylosing Spondylitis: From Traditional Scores to Machine Learning Assessment 113
). IL-6 e TGF-b1 nel siero e nei sovranatanti di cellule mononucleate in pazienti con sclerosi sistemica (SSC). 112
Aberrant cytokine expression and severity of the infiltrates are reverted by rituximab therapy in salivary glands of patients with Sjogren’s syndrome 109
Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts 109
Activation antigens and adhesion molecules expression on Vd1+ T cells in systemic sclerosis (SSc) 107
Recent advances and evolving concepts in Still's disease 105
Cytokine storm syndrome in severe COVID-19 105
Correction to: Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study 104
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 104
EULAR/PReS recommendations for the diagnosis and management of Still's disease, comprising systemic juvenile idiopathic arthritis and adult-onset Still's disease 102
EVIDENCE FOR REDUCED ANGIOGENESIS IN BONE MARROW (BM) IN SYSTEMIC SCLEROSIS (SSC) 102
Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data 101
Association between clinical, histopathological and molecular features in primary Sjogren's Syndrome: a retrospective study 100
Development and implementation of the AIDA International Registry for patients with Behçet's disease 99
Clinical features and prognosis of COVID-19 in people with spinal cord injury: a case–control study 97
How the different systemic organ involvements are overlapped in patients with primary Sjogren syndrome: analysis using a mathematical model 96
Benefits of anakinra versus TNF inhibitors in rheumatoid arthritis and type 2 diabetes: long-term findings from participants furtherly followed-up in the TRACK study, a multicentre, open-label, randomised, controlled trial 96
The Relationship Between Metabolic Syndrome and Pain Catastrophizing in Psoriatic Arthritis 95
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 95
Pain catastrophizing negatively impacts drug retention rate in patients with Psoriatic Arthritis and axial Spondyloarthritis: results from a 2-years perspective multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica) study 94
Cardiovascular disease in primary sjögren’s syndrome 90
The Effect of Ketogenic Diet on Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review 90
Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort 88
SARS-CoV-2 infection in patients with primary Sjögren syndrome: characterization and outcomes of 51 patients 88
The economic burden of fibromyalgia: A systematic literature review 86
Polyclonal B lymphocyte activation in progressive systemic sclerosis. 85
The specialized pro-resolving lipid mediator Protectin D1 affects macrophages differentiation and activity in Adult-onset Still's disease and COVID-19, two hyperinflammatory diseases sharing similar transcriptomic profiles 85
Interstitial Lung Disease and Pulmonary Damage in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis 83
Development and Implementation of the AIDA International Registry for Patients With VEXAS Syndrome 82
Association between Patient Acceptable Symptom State and disease activity in psoriatic arthritis is disrupted by confounders, including comorbid fibromyalgia 81
Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis 80
Clinical targeted treatment in Sjogren's disease: A systematic literature review for an evidence-based medicine approach 77
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 77
Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases 77
Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis 75
EULAR Textbook on Rheumatic Diseases – Third Edition (2018) 74
Correction: Clinical and laboratory features associated with macrophage activation syndrome in Still’s disease: data from the international AIDA Network Still’s Disease Registry 73
The evaluation of type I interferon score in dermatomyositis, a systematic review and a meta-analysis 72
Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study 72
Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases 71
The Vessels Contribute to Fibrosis in Systemic Sclerosis 71
SCLERODERMA FIBROBLASTS SUPPRESS ANGIOGENESIS VIA TGF-beta/CAVEOLIN-DEPENDENT SECRETION OF PIGMENTED EPITHELIUM DERIVED FACTOR: TGF-beta RECEPTOR INHIBITORS AS A NOVEL THERAPEUTIC TARGET FOR THE TREATMENT OF SCLERODERMA 71
A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome 71
Association Between the Use of Oral Contraceptives and the Development of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis 70
Primary versus systemic-sclerosis-associated Raynaud's phenomenon: relationship with clinical and environmental factors 69
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis 68
Vascular complications of scleroderma 67
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 67
Beyond the joints, the extra-articular manifestations in rheumatoid arthritis 67
The assessment of the drug retention rate of secukinumab in patients with psoriatic arthritis in a real-life multicentre cohort 66
Novel biomarker for pulmonary vascular disease in systemic sclerosis patients 66
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? 66
Interleukin-25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjögren's Syndrome 66
The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational “real-life” study 65
New biologic (Ab-IPL-IL-17) for IL-17-mediated diseases: identification of the bioactive sequence (nIL-17) for IL-17A/F function 65
Interstitial lung disease in systemic sclerosis: Pathophysiology and therapy 65
Systemic Sjogren presenting without sicca syndrome: characterization of 240 patients according to the new 2017 ACR/EULAR Classification Criteria 65
Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications 64
Factors influencing the patient evaluation of injection experience with the SmartJect autoinjector in rheumatoid arthritis. 62
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 62
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 62
Systemic sclerosis interstitial lung disease: unmet needs and potential solutions 61
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 61
Effectiveness of Golimumab as Second Anti-TNFα Drug in Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Axial Spondyloarthritis in Italy: GO-BEYOND, a Prospective Real-World Observational Study 61
Co-Occurrence of Anti-Synthetase Syndrome and Sjögren Disease: A Case-Based Review 60
Totale 11.419
Categoria #
all - tutte 236.669
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 236.669


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022648 0 5 29 4 7 2 4 4 55 29 19 490
2022/2023318 5 15 11 28 73 13 6 7 10 11 130 9
2023/20241.786 60 216 61 144 198 839 32 85 17 51 40 43
2024/202510.867 230 179 617 113 109 364 242 64 1.422 1.088 3.012 3.427
2025/202616.017 1.556 496 1.216 2.243 456 944 4.069 1.311 1.231 1.258 801 436
Totale 29.636